Skip to main content
main-content
Top

Expert commentary: DEPICT-1 and inTandem3

Parth Narendran discusses the findings of two trials testing SGLT2 inhibitors in patients with type 1 diabetes (5:47).
Read the accompanying news stories on the DEPICT-1 and inTandem3 results

More on this topic